Trials / Completed
CompletedNCT04281095
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
A Phase I/II Randomized, Double Blind, Active-controlled, Single Center Clinical Trial for Evaluation of Safety and Efficacy of ATGC-110, An Intramuscularly Administered Clostridium Botulinum Neurotoxin Type A, in Adult Patients With Moderate to Severe Glabellar Frown Lines
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- ATGC Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum toxin type A | Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
- First posted
- 2020-02-24
- Last updated
- 2020-07-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04281095. Inclusion in this directory is not an endorsement.